Skip to main content

Gibson Christopher's Form 4 filing

Recursion Pharmaceuticals, Inc. (RXRX) · filed May 5, 2023

Accession no.
0001209191-23-027830
Filed
May 5, 2023
Trade date
Jan 5-May 3, 2023
Filing delay
120 daysLate
Rule 10b5-1 plan
Not checked

This filing lists 17 non-derivative transactions and 8 derivative transactions. Open-market sales total $278.3K. It was filed 120 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gibson ChristopherCIK 0001856369Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 5, 2023Class A Common StockCConversionAcquired+3,000$0.00$0966,710Direct
Jan 5, 2023Class A Common StockGGiftDisposed−3,000$0.00$0963,710Direct
Feb 2, 2023Class A Common StockCConversionAcquired+3,000$0.00$0966,710Direct
Feb 2, 2023Class A Common StockGGiftDisposed−3,000$0.00$0963,710Direct
Mar 2, 2023Class A Common StockCConversionAcquired+3,000$0.00$0966,710Direct
Mar 2, 2023Class A Common StockGGiftDisposed−3,000$0.00$0963,710Direct
May 3, 2023Class A Common StockGGiftDisposed−8,662$0.00$0955,048Direct
May 3, 2023Class A Common StockCConversionAcquired+1,338$0.00$0956,386Direct
May 3, 2023Class A Common StockGGiftDisposed−1,338$0.00$0955,048Direct
May 3, 2023Class A Common StockMOption exerciseAcquired+31,250$2.48+$77,500986,298Direct
May 3, 2023Class A Common StockSSaleDisposed−33,073$4.71F5−$155,773.83953,225Direct
May 3, 2023Class A Common StockCConversionAcquired+4,000$0.00$04,000Indirect
May 3, 2023Class A Common StockSSaleDisposed−4,000$4.91F7−$19,6400Indirect
May 3, 2023Class A Common StockCConversionAcquired+20,000$0.00$020,000Indirect
May 3, 2023Class A Common StockSSaleDisposed−20,000$4.90F7−$98,0000Indirect
May 3, 2023Class A Common StockCConversionAcquired+1,000$0.00$01,000Indirect
May 3, 2023Class A Common StockSSaleDisposed−1,000$4.92F10−$4,9200Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 3, 2023Class A Common StockMOption exerciseDisposed−31,250$0.00$0625,000Direct
Jan 5, 2023Class A Common StockCConversionDisposed−3,000$0.00$06,558,834Direct
Feb 2, 2023Class A Common StockCConversionDisposed−3,000$0.00$06,555,834Direct
Mar 2, 2023Class A Common StockCConversionDisposed−3,000$0.00$06,552,834Direct
May 3, 2023Class A Common StockCConversionDisposed−1,338$0.00$06,551,496Direct
May 3, 2023Class A Common StockCConversionDisposed−4,000$0.00$0531,000Indirect
May 3, 2023Class A Common StockCConversionDisposed−20,000$0.00$0488,000Indirect
May 3, 2023Class A Common StockCConversionDisposed−1,000$0.00$0122,875Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F5

This transaction was executed in multiple trades at prices ranging from $4.55 to $5.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F7

This transaction was executed in multiple trades at prices ranging from $4.57 to $5.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 2 transactions in Table I.

F10

This transaction was executed in multiple trades at prices ranging from $4.64 to $5.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)